Interview with BlockRX

Questions:

1. What technology solutions do you provide? We focus on bringing decentralized digital ledger solutions based on Blockchain Technology to the Pharma Industry. Our goal is to provide Visibility, Traceability and Integration across the Drug Supply Chain. 

2. When the company was founded? Back in 2015 a group of 4 smart and visionary individuals came together to start this journey with iSolve. BlockRx was an initiative developed by iSolve in 2016.

 3. Why was the company founded? iSolve was created to provide innovation to pharma with the blockchain and help bring Life Saving Drugs to Market. BlockRx was created as an initiative to help pharma companies and solution providers get involved with the blockchain. 

 4. Organization’s purpose: What we do, how do we do it, whom do we do it for, What value are we bringing? We believe in the sum of all parts make a whole. Each of our members brings an individual expertise that provides an equal benefit towards developing this unique offering for the Bio/Pharmaceutical industry. From the beginning we wanted to bring an unique solution to addressing the many growing challenges with a globalized pharmaceutical sector – security, lack of data interoperability, siloed and fragmented operational structures. Combining our knowledge of the pharmaceutical framework and the blockchain technology, we challenged ourselves to “shake up” the industry by introducing an emerging technology to address the many legacy problems. We knew the challenge to bring this to market would be grinding and difficult but we also knew if we could pioneer the adoption into the pharmaceutical sector we would open new doors while making an impact on an industry and ultimately helping patients. The value we bring is our expertise – we know the pharmaceutical framework, we speak their language, we understand their compliance challenges. We understand the nuances of blockchain and know how to apply it in that framework. We are not trying to be everything to everyone; our offering is exclusive to markets where the safety risk to patients and consumers are at the highest level and where we have built our expertise. 

 5. Scope of Operations: what kind of product or service do your provide? We offer a comprehensive solution – product and service. The product we deliver is a platform where a Pharmaceutical company can manage, store, verify, distribute, share and secure information of a transactional nature in a  trusted environment in order to improve the health of the pharmaceutical supply chain and the patients it serves.  The service we offer is our combined expertise in the pharmaceutical industry and the technology so that we can effectively help pharmaceutical companies strategize and transform their operations to proactively compete in new patient-driven healthcare system. 

 6. What is your future vision? Our vision is to have global expansion to help support the Pharma community in every country. We have a company roadmap that identifies the goals and deliverables for our company in providing blockchain solutions for the Life Sciences Industry.  

 7. History of the project The principals came together with this project based on the premise there were no fully operational solutions to address the growing need and concern over sharing data in a trusted environment with trusted partners. This concern combined with the desire for partners to better collaborate and harmonize while dealing with a growing epidemic of counterfeit drugs and increased demands from the regulatory agencies.

 8. Motivation to develop the project Our continued commitment is to provide biotech, pharma and healthcare companies with the tools and knowledge to create a secure, private and shared network that allows them to successfully implement their strategic initiatives. Our management team is comprised of highly skilled professionals and entrepreneurs with more than 80 years of combined experience in Finance, Technology, Pharmaceutical, Healthcare, Medical, and Government sectors. As a result our team has the knowledge and the agility to identify opportunities in the market and have the ability to rapidly deploy solutions through the extensive use of automation and integration with secure and robust platforms. 

 9. What makes your project unique and valuable? What makes our project unique is we are the only blockchain company that is directly involved in the Pharma space and our ecosystem will support participation from Patients as well as Pharma companies.

 10.What is your token. The BKRx Token provides functionality in a variety of ways: (1) For membership (2) For Network Access (3) For Data Exchange and (4) For incentives.

 11.What is the token supply? 300 million BKRxTokens will be minted 

12.What is code base that your product is using? We are a blockchain agnostic solution; however, our proprietary API’s are developed to integrate with Pharma ERP systems, Content Management and  PPM Systems

 13. What features does your program use? Our solution provides the ability to integrate and view information from disparate systems and allows global visibility and tracking. Our solutions allow us to support supply chain models, clinical trial models and regulatory models.

 14. Who are your competitors and how are you superior to them? There are many great technology companies working in the area of blockchain and DLTs. However we find that our solution is unique as we are offering a comprehensive go-to-solution with the Pharma Blockchain Ecosystem combined with the unmatched expertise of the pharmaceutical framework. 

 15.Is there any mining or staking involved with your coins? The BlockRx Token will be awarded to all active Blockchain participants of the network, including trusted participants leveraging the BlockRx platform as a Delegated Proof of Stake. The BlockRx Token will provide incentive and a medium of exchange among trade partners and investors, while providing product value with consumer availability on digital token exchanges. 

 16.What are the future plans for your project? In the near future, we plan to continue to refine the Pharma Blockchain Ecosystem through Resource Acquisitions and working with our clients and partners to ensure successful installations of this technology. On a longer term we intend to redefine Life Science Innovation with our robust Pharma Blockchain Ecosystem including ADLT, Intel’s Sawtooth and the BlockRx Token.

 17.What other services will be offered by your project or company in the future? We are currently researching other applications within the pharmaceutical framework that would benefit from the solution especially in the area of postmarketing surveillance, clinical trials, intellectual property acquisition, and other services throughout the drug development lifecycle. 

 18.What can we expect from the project in the next 6-12 months? In the next 6-12 months our goal is to work with our pharma clients in progressing their current status either at POC or pilot phase to the next logical step towards implementing the Pharma Ecosystem to address their operational challenges 

 19.What is your expected company profitability in 2018 Our 2018 projections will partially be based on the outcome of our ICO given the completion in Q4 2017.

 20.Expenses and current cost of operations? Our cost/revenue model will drastically change in 2018 thus we are moving to growth model to determine costs and revenue.

 21.What will you use your investment capital for? We plan to re-invest back into BlockRx as we are recruiting top global talent to support product development and operations and ensure that we meet clients’ expectations on service and quality.

 22.Does your token pass the howey test? We have a team of legal experts who work diligently to ensure that our offering is compliant and will meet our investors’ expectations. 

 23.Growth strategy after the ICO? As we mentioned, we have a research team exploring other areas of the framework where this system could be applied. As we progress on client installations of the technology on the supply chain, we will combine real-world diligence and exploratory research to expand our services into the areas of Clinical Trials, Pharma Labeling and Patient Adherence Programs.

 24.How many tokens do the founders get? 30% the coins minted will go to the Principals.

 25.What exchanges will this token be traded on? We are Erc20 Ethereum compatible token and are tradable on every exchange and we will be making that announcements shortly 

 26.How will you grow your market? Our mission is to work with entities that offer products that satisfy a critical need yet potentially pose a critical threat when gone wrong – food and medicine. We believe in a strategic and target approach to market entrance. With that we started with the Pharmaceutical supply chain which is ripe for the blockchain solution and then we will strategically move to the next area that is ready to embrace this redefining solution. Given the global nature of the entities we serve we will grow organically and aligned with our core mission. 

27.What is the target demographic? Today our current demographic is any Pharma Company with a Supply Chain. Tomorrow we plan to work with entities in the areas of food and medicine which are both equally at risk for tampering and counterfeit and can be detrimental to the patient/consumers’ health. 

 28.Do you have any active partnerships? Our strategic partnerships have been an instrumental part of our growth. We have partnered with leaders across the global pharmaceutical industry via our Direct Partner Channel. By leveraging our partner network, we can manage the pharmaceutical landscape by providing unique solutions based on industry needs and knowledge. Our partner channel has expanded over the past two years to include additional pharma use cases, enabling us to expand our service offerings across a variety of verticals within life sciences and healthcare. These partnerships will support the longevity of our solution and the exponential adoption of the BlockRx Token.

 29.What are the nature of these relationships and how are you utilizing or leveraging these partnerships?  Our Strategic Partnerships are based on sharing a similar vision to provide visibility, transparency and integration within the pharmaceutical value chain while protecting the safety of its patients. Our Relationships consists of Trusted Partners that we work with on a daily basis to expand a shared offering to innovate Pharma with the Blockchain. 

 30.What is vision for the company in the next 3-5 year plan? Our vision is to have global expansion and the ability to integrate the Pharma community with ADLT™ and the Blockchain 31.Please provide information about the backgrounds of your CEO, CTO, CFO. Kasia Piskorska – “Master of Serial Financial Management” Principal and CFO with more than 13 years experience in Portfolio Management, Financial Management, Business Management, and Project Management with Fortune 500 companies. She is responsible for financial reporting and strategic partnerships as well as the development of new revenue channels for supporting iSolve and BlockRx 

 31.Please provide information about the backgrounds of your CEO, CTO, CFO.

 Kasia Piskorska – “Master of Serial Financial Management” Principal and CFO with more than 13 years experience in Portfolio Management, Financial Management, Business Management, and Project Management with Fortune 500 companies. She is responsible for financial reporting and strategic partnerships as well as the development of new revenue channels for supporting iSolve and BlockRx

Dr. Darryl Glover – “The Mad Scientist” Principal, Chief Clinical Officer and Serial Entrepreneur with 18 years’ experience in business development and start-ups. Darryl is responsible for the solutions and services offerings of iSolve and BlockRx and is currently acting COO of the enterprise.

 Carlos Sanchez – “The Emerging Tech Enabler” Principal & CTO responsible for technology solutions and vision to ensure positioning as a digital enterprise for all B2B channels across all industries served. He is the resident expert in Cryptocurrency Technologies, Integration Strategy, E-commerce, and System Architecture.

 Gordon Tampol – “The Visionary” Principal and CEO and Member of the Board of Directors Entrepreneur and long-time strategist for Fortune 500 companies in multiple disciplines and sectors. Responsible for the leadership and strategic vision for iSolve and BlockRx. If you want to learn more about our team and the project visit our website http://www.blockrx.com/.